View in EDS HTML Full Text PDF Full Text

Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Saved in:

Bibliographic Details
Title:	Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.
Authors:	Ntellas, Panagiotis¹ (AUTHOR), Park, Haeseong² (AUTHOR), Culm, Kerry³ (AUTHOR), Lee, Jeeyun⁴ (AUTHOR), Youssoufian, Hagop^3,5 (AUTHOR), Mockbee, Colleen³ (AUTHOR), Uhlik, Mark³ (AUTHOR), Benjamin, Laura³ (AUTHOR), Chau, Ian¹ (AUTHOR) ian.chau@rmh.nhs.uk
Source:	Current Oncology. Jun2026, Vol. 33 Issue 6, p319. 18p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	11980052
DOI:	10.3390/curroncol33060319